Conduit Pharmaceuticals Inc (CDT)
$0.12
+0.01
(+13.67%)▲
Performance
- $0.11$0.16$0.12
8.33%
Downside
Day's Volatility :29.89%
Upside
23.52%
- $0.10$7.83$0.12
20.83%
Downside
52 Weeks Volatility :98.79%
Upside
98.47%
Returns
| Period | Conduit Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -51.5% | 0.0% |
6 Months | -96.39% | 0.0% |
1 Year | -93.39% | 0.0% |
3 Years | -98.88% | -21.1% |
Highlights
Market Capitalization | 9.8M |
Book Value | - $0.07 |
Earnings Per Share (EPS) | -0.08 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -322.02% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -0.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Conduit Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Conduit Pharmaceuticals Inc | -13.26% | -96.39% | -93.39% | -98.88% | -98.88% |
 Regeneron Pharmaceuticals, Inc. | -11.94% | 13.03% | 20.97% | 85.64% | 232.53% |
 Novo Nordisk A/s | -12.38% | -3.12% | 17.52% | 138.65% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 7.18% | 92.5% | 69.12% | 39.45% | 259.26% |
 Vertex Pharmaceuticals Incorporated | -0.75% | 21.23% | 29.84% | 165.64% | 177.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Conduit Pharmaceuticals Inc | NA | NA | NA | 0.0 | 0.0 | -3.22 | NA | -0.07 |
Regeneron Pharmaceuticals, Inc. | 26.88 | 26.88 | 1.38 | 45.01 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.8 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Conduit Pharmaceuticals Inc | NA | $9.8M | -98.88% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.1B | 232.53% | 26.88 | 32.04% |
Novo Nordisk A/s | Buy | $523.9B | 361.43% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $124.3B | 177.5% | 32.84 | -4.74% |
Insights on Conduit Pharmaceuticals Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.1% return, outperforming this stock by 162.5%
Company Information
Organization | Conduit Pharmaceuticals Inc |
Employees | 7 |
CEO | Dr. David Joszef Tapolczay |
Industry | Miscellaneous |
Discover More
Metal Sky Star Acquisition Corp
$0.12
+13.67%
Stone Ridge 2054 Longevity Income Etf
$0.12
+13.67%
Nabors Energy Transition Corp Ii
$0.12
+13.67%
Dimensional Us Core Equity 1 Etf
$0.12
+13.67%
Natuzzi Spa
$0.12
+13.67%
Swan Hedged Equity Us Lg Cap
$0.12
+13.67%
Jpmorgan Activebuilders Emer
$0.12
+13.67%
Blackrock Income Trust Inc
$0.12
+13.67%
Roundhill Ball Metaverse Etf
$0.12
+13.67%